|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre,randomised,phase 3non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，： | 1 |
| 2 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre,randomised,phase 3non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，： | 1 |
| 3 | Bendamustine:rebirth of an old drug显示文摘 | Cheson BD Rummel MJ | 2009 | J Clin Oncol2009，27，9： | 1 |
| 4 | Bendamustine Plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an openlabel,multicentre,randomised,phase 3 non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 5 | Bendamustine plus rituximab versusCHOP plus rituximab as first-line treatmentfor patients with indolent and mantle-celllymphomas: an open-label, multicentre,randomised, phase 3 non-inferiority trial 显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 6 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre,randomised,phase 3 non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 7 | Bendamustine plus rituximab versusCHOP plus rituximab as first-line treatmentfor patients with indolent and mantle-celllymphomas: an open-label, multicentre,randomised, phase 3 non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 8 | Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma显示文摘 | Rummel MJ Al-Batran SE Kim SZ | 2005 | J Clin Oncol2005，23，15： | 1 |
| 9 | Bendamustine plus rit-uximab is effective and has a favorable toxicity profile in the treat-ment of mantle cell and low-grade non-Hodgkin’s lymphoma显示文摘 | Rummel MJ Al-Batran SE Kim SZ | 2005 | JClin Oncol2005，23，15： | 1 |
| 10 | Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma显示文摘 | Rummel MJ Al-Batran SE Kim SZ | 2005 | J Clin Oncol2005，23，15： | 1 |
| 11 | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity显示文摘 | Boger CA Rummele P Mihatsch MJ | 2006 | Am J Transpl2006，6，8： | 1 |
| 12 | Phase II trial of biweekly infusional fluorouracil,folinic acid, and oxaliplatin in patients with advanced gastric cancer显示文摘 | Al-Batran SE Atmaca h Hegewisch- Becker S Jaeger D Hahnfeld S Rummel MJ | 2004 | J ClinOncol2004，22，4： | 1 |
| 13 | Bendamustine plusrituximab versus CHOP plus rituximab as first-line treatment for patientswith indolent and mantle-cell lymphomas: an open label, multicentre,randomised, phase 3 non-inferiority triai显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，： | 1 |
| 14 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre,randomised,phase 3 non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 15 | Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma显示文摘 | Rummel MJ Al-Batran SE Kim SZ | | 0，，15： | 1 |
| 16 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial 显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 17 | Bendamustine plus rituximab versus CHOP plus fituximab as first-line treatment for patients with indo- lent and mantle-cell lymphomas : an open-label, multicentre ,randomised, phase 3 non-inferlority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，9873： | 1 |
| 18 | Bendamustine plus rituximab versus CHOP plus rimximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre,randomised,phase 3 non-inferiority trial显示文摘 | Rummel MJ Niederle N Maschmeyer G | 2013 | Lancet2013，381，： | 1 |
| 19 | Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases 显示文摘 | Chow KU Sommerlad WD Boehrer S Schneider B Seipeh G Rummel MJ | 2002 | Haematologica2002，87，1： | 1 |
| 20 | Bendamustine : rebirth of an olddrug显示文摘 | CHESON BD RUMMEL MJ | 2009 | J Clin Oncol2009，27，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员